Effect of the CYP3A5 and ABCB1 genotype on exposure, clinical response and manifestation of toxicities from sunitinib in Asian patients
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Effect of the CYP3A5 and ABCB1 genotype on exposure, clinical response and manifestation of toxicities from sunitinib in Asian patients
Authors
Keywords
-
Journal
PHARMACOGENOMICS JOURNAL
Volume 16, Issue 1, Pages 47-53
Publisher
Springer Nature
Online
2015-03-17
DOI
10.1038/tpj.2015.13
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efflux pump ABCB1 single nucleotide polymorphisms and dose reductions in patients with metastatic renal cell carcinoma treated with sunitinib
- (2014) Benoit Beuselinck et al. ACTA ONCOLOGICA
- Sunitinib in metastatic renal cell carcinoma: An ethnic Asian subpopulation analysis for safety and efficacy
- (2014) Se-Hoon Lee et al. Asia-Pacific Journal of Clinical Oncology
- Practical Guidelines for Therapeutic Drug Monitoring of Anticancer Tyrosine Kinase Inhibitors: Focus on the Pharmacokinetic Targets
- (2014) Huixin Yu et al. CLINICAL PHARMACOKINETICS
- Association Analysis of Genetic Polymorphisms in Genes Related to Sunitinib Pharmacokinetics, Specifically Clearance of Sunitinib and SU12662
- (2014) M H M Diekstra et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- The Effect of ABCG2 Genotype on the Population Pharmacokinetics of Sunitinib in Patients With Renal Cell Carcinoma
- (2014) Tomoyuki Mizuno et al. THERAPEUTIC DRUG MONITORING
- Role of sunitinib and SU12662 on dermatological toxicities in metastatic renal cell carcinoma patients: in vitro, in vivo, and outcomes investigation
- (2013) Yi Ling Teo et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Midazolam as a phenotyping probe to predict sunitinib exposure in patients with cancer
- (2013) D. de Wit et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients
- (2013) Hye Ryun Kim et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- CYP3A4*22: promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy
- (2012) Laure Elens et al. PHARMACOGENOMICS
- Sorafenib and Sunitinib, Two Anticancer Drugs, Inhibit CYP3A4-Mediated and Activate CY3A5-Mediated Midazolam 1'-Hydroxylation
- (2011) M. Sugiyama et al. DRUG METABOLISM AND DISPOSITION
- Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study
- (2011) Jesus Garcia-Donas et al. LANCET ONCOLOGY
- The Efficacy and Safety of Sunitinib in Korean Patients with Advanced Renal Cell Carcinoma: High Incidence of Toxicity Leads to Frequent Dose Reduction
- (2010) C. Yoo et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis
- (2009) Brett E. Houk et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A Population Pharmacokinetic Meta-analysis of Sunitinib Malate (SU11248) and Its Primary Metabolite (SU12662) in Healthy Volunteers and Oncology Patients
- (2009) B. E. Houk et al. CLINICAL CANCER RESEARCH
- A routine feasible HPLC analysis for the anti-angiogenic tyrosine kinase inhibitor, sunitinib, and its main metabolite, SU12662, in plasma
- (2009) Marie-Christine Etienne-Grimaldi et al. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES
- Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial
- (2009) Martin E Gore et al. LANCET ONCOLOGY
- MDR1 (C3435T) polymorphism: relation to the risk of breast cancer and therapeutic outcome
- (2009) M Cizmarikova et al. PHARMACOGENOMICS JOURNAL
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now